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Abstract	  Metabolomics	  is	  a	  recent	  science	  that	  could	  be	  defined	  as	  the	  comprehensive	  qualitative	  and	   quantitative	   analysis	   of	   all	   small	   molecular	   weight	   compounds	   present	   in	   a	   cell,	  organ	   (including	   biofluids)	   or	   organism	   at	   a	   specific	   time	   point.	   More	   and	   more	  applications	   have	   been	   found	   these	   last	   years	   to	  metabolomics	   in	   the	   pharmaceutical	  field.	  Specifically	  in	  the	  drug	  discovery	  process,	  metabolomics	  open	  new	  perspectives,	  in	  new	   targets	   identification,	   in	   toxicological	   studies	   and	   in	   bioactive	   natural	   products	  discovery.	   	  The	  challenge	  in	  metabolomics	   is	  to	   find	  a	  technological	  approach	  allowing	  the	  reproducible	   identification	  and	  quantitation	  of	  as	  much	  metabolites	  as	  possible.	   In	  this	   context,	   mass	   spectrometry	   and	   NMR	   are	   emerging	   as	   key	   and	   complementary	  technologies.	  
	  
Introduction	  Metabolomics	  is	  the	  newest	  of	  the	  “omics”	  sciences,	  part	  of	  “functional	  genomics”	  with	  genomics,	   transcriptomics	   and	   proteomics	   (Figure	   1).	   As	   defined	   by	   Fiehn	   in	   2001,	  metabolomics	   could	  be	   considered	  as	   the	   “comprehensive	  qualitative	  and	  quantitative	  analysis	   of	   all	   metabolites	   	   (=	   small	   molecular	   weight	   compounds	   =	   metabolome)	  present	  in	  a	  cell,	  an	  organ	  or	  an	  organism	  at	  a	  specific	  time	  point”	  [1].	  The	  compounds	  generally	  considered	  as	  metabolites	  are	  molecules	  with	  a	  molecular	  weight	   inferior	   to	  2000	   Da.	   It	   could	   be	   primary	  metabolites	   such	   as	   sugars,	   amino	   acids,	   organic	   acids,	  fatty	   acids,	   energetic	   metabolites,	   nucleotides,	   urea	   metabolites,…	   In	   plants	   or	  microorganisms,	   secondary	   metabolites	   presenting	   a	   very	   huge	   structural	   diversity	  could	   also	   be	   found.	   A	   metabolome,	   and	   more	   particularly	   the	   human	   metabolome,	  
consists	  in	  a	  mixt	  of	  both	  endogenous	  and	  exogenous	  compounds	  [2].	  	  Actually,	  several	  thousands	  of	  human	  metabolites	  have	  been	  described	  and	   could	  be	   accessed	   freely	   in	  the	   “Human	   Metabolome	   Database”	   which	   offers	   detailed	   informations	   about	   around	  40,000	   endogenous	   and	   exogenous	   metabolites	   [2].	   Up	   to	   200	   000	   metabolites	   are	  estimated	  to	  occur	  in	  the	  plant	  kingdom	  [1].	  	  The	  study	  of	  metabolites	  is	  in	  reality	  very	  old,	  and	  saccharose,	  isolated	  for	  the	  first	  time,	  from	  beets,	   in	   1747	   by	  Marggraf	   (but	   its	   structure	   only	   determined	   at	   the	   end	   of	   the	  XIXth	  Century)	   could	  be	   considered	   as	   one	  of	   the	   first	  metabolite	   isolated	   [3].	   Even	   if	  metabolites	  are	  studied	   in	  various	  organisms	  since	  numerous	  years,	   ‘metabolomics’	   in	  its	  actual	  acceptation	   is	  very	  recent.	  The	   first	  paper	   that	  could	  be	  considered	  as	  a	  real	  “metabolomics”	   analysis	   is	   the	   paper	   from	   Arthur	   B.	   Robinson	   and	   Linus	   Pauling	   in	  1971,	   dedicated	   to	   the	   analysis	   of	   urine	   vapour	   and	   breath	   metabolites	   using	   gas	  chromatography.	  In	  this	  paper,	  250	  metabolites	  were	  analysed	  and	  identified	  in	  breath,	  and	  280	  in	  urine	  vapour	  [4].	  Nevertheless,	  the	  first	  mention	  of	  the	  term	  “metabolome”	  in	  the	   literature	   was	   only	   in	   1998	   (as	   sorted	   by	   bibliographic	   engines)	   in	   a	   paper	   of	   S.	  Oliver	  about	  the	  functional	  analysis	  of	  the	  yeast	  genome	  [5].	  The	  word	  “metabolomics”	  was	  then	  only	  used	  in	  about	  5	  scientific	  publications	  in	  2001,	  but	  already	  in	  2004	  was	  created	   the	   “metabolomics	   society”1.	   Since	   then,	   there	  was	   an	   exponential	   increase	   in	  the	  number	  of	  publications	  per	  year	  about	  metabolome,	  metabolomic	  or	  metabolomics,	  reaching	  a	  number	  of	  around	  2168	  publications	  in	  2013	  (Figure	  2).	  	  	  In	  1999,	  the	  term	  “metabonomics”	  was	  also	  introduced	  by	  Nicholson	  and	  colleagues	  in	  a	  paper	   where	   it	   was	   defined	   as	   “the	   quantitative	   measurement	   of	   the	   dynamic	  multiparametric	  metabolic	   response	  of	   living	   systems	   to	  physiopathological	   stimuli	   or	  genetic	   modifications”[6].	   Nowadays,	   the	   term	   metabolomic(s)	   is	   the	   most	   currently	  used,	  as	  it	  could	  clearly	  be	  seen	  in	  Figure	  2.	  The	  concept	  metabonomics	  is	  nevertheless	  still	  used,	  particularly	  for	  the	  study	  of	  dynamic	  changes	  in	  the	  metabolome,	  mainly	  in	  the	  toxicological	  field.	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In	   all	   cases,	   a	   metabolomic	   analysis	   consists	   in	   the	   identication	   of	   modifications	   in	   a	  metabolome,	  modifications	  that	  could	  be	  related	  to	  internal	  or	  external	  causes.	  Internal	  causes	  are	  generally	  correlated	  with	  genetic	  variations,	  i.e.	  the	  study	  of	  two	  genetically	  close	  organisms	  (taxonomic	  studies)	  or	  study	  of	  the	  influence	  of	  a	  gene	  modification	  on	  the	  metabolome.	  External	  causes	  of	  modification	  for	  the	  metabolome	  could	  be	  in	  a	  cell	  or	  an	  organism	  the	  administration	  of	  a	  drug	  or	  a	  toxic,	  or	  pathology.	  An	  external	  cause	  could	  also	  be	  different	  environmental	  conditions	  (including	  lifestyle	  and	  alimentation,	  or	  culture	  conditions	  for	  plants),	  different	  conservation	  conditions	  or	  different	  conditions	  of	   extraction.	   Ideally,	   a	   complete	  metabolomics	   study	   should	   identify	   the	  metabolites	  that	  are	  modified	  and	  this	  could	  lead	  to	  the	  comprehension	  of	  a	  metabolic	  pathway,	  to	  the	  identification	  of	  bioactive	  compounds	  or	  to	  the	  determination	  of	  the	  mode	  of	  action	  of	   a	   drug.	  The	   fields	   of	   application	  of	  metabolomics	   are	   then	  huge,	   ranging	   from	   food	  analysis	   and	   nutrition	   [7,8]	   (were	   the	   techniques	   are	   also	   routinely	   used	   by	   the	   food	  industry)	   to	   functional	  genomics	  applications.	  More	  particularly	   in	   the	  pharmaceutical	  field,	   metabolomic	   techniques	   and	   applications	   find	   scope	   from	   drug	   discovery	   to	  clinical	   development	   of	   new	   medicines.	   	   This	   includes	   target	   identification	   and	  validation,	   elucidation	  of	   the	  mechanisms	  of	   action	  of	  drugs,	   lead	   identification	   [9,10],	  identification	  of	  drug	  efficacy	  or	  pathology	  biomarkers	  [11–13],	  toxicological	  analysis	  by	  identification	   of	   safety	   biomarkers	   [14–16]	   but	   also	   quality	   control,	   particularly	   of	  medicinal	   plants	   [17,18]	   and	   bioactive	   drug	   discovery	   from	   natural	   sources	   [19]	   .	  Recently,	   several	   reviews	   have	   highlighted	   the	   potential	   of	  metabolomics	   in	   the	   drug	  discovery	  process	   [20-­‐22].	  The	  challenge	   in	  metabolomics	   is	   then	   to	   find	  an	  analytical	  technique	  or	  a	  technological	  approach,	  combined	  with	  adequate	  statistical	  analysis,	  that	  allows	   the	   detection	   and	   the	   identification	   of	   the	   highest	   possible	   number	   of	  metabolites.	  	  
	  
Technological	  approaches	  As	  described	  above,	  one	  of	  the	  objectives	  of	  metabolomics	  in	  the	  pharmaceutical	  field	  is	  to	   identify	   and	   quantify	   specific	   metabolic	   markers	   susceptible	   to	   improve	   quality	  control,	   improve	   early	   diagnosis,	   survey	   therapeutic	   outcomes	   and	   facilitate	   the	  development	  of	  novel	  drugs	  candidates	  [23-­‐25].	  	  	  
The	  methodology	  relies	  on	  differential	  metabolic	  expression	  profiling.	  The	  fundamental	  approach	   is	  based	  on	  the	  assumption	  that	   the	  pathology	  of	  concern	  or	   the	   therapeutic	  treatment	  (i.e.	  drug	  or	  drug	  candidate)	  will	  affect	  some	  physiological	  processes	  causing	  changes	  in	  the	  metabolic	  expression	  levels.	  Metabolic	  generating	  similar	  signals	  in	  both	  sample	   groups	   are	   ignored	   while	   significantly	   up-­‐	   and	   down	   regulated	   metabolites	  become	  potential	  biomarkers.	  Differential	  expression	  profiling	  requires	  both	  a	  sensitive	  technology	   to	   discern	   any	   tiny	   differences	   and	   a	   high	   throughput	   system	   in	   order	   to	  process	  large	  series	  of	  samples	  required	  to	  reach	  statistical	  significance.	  	  Besides	   “metabolic	   fingerprinting”	   that	   consists	   in	   the	   comparison	   of	   metabolic	  fingerprints,	   without	   identification	   of	   particular	   metabolites,	   there	   are	   two	   general	  approaches,	   target	   specific	   and	   global	   or	   non-­‐directed,	   for	   metabolomic	   biomarker	  discovery.	   Target-­‐specific,	   or	   biology	   driven,	   approach	   frequently	   uses	   mass	  spectrometry	   and	   is	   useful	   for	   validation	   and	   routine	   clinical	   analysis.	   In	   that	   case,	  tested	  metabolites	   are	   typically	   selected	  on	   the	  basis	   of	   current	   knowledge	  of	   disease	  mechanism	   and	   pathophysiology.	   Global/non-­‐directed	   approaches	   may	   have	   more	  potential	   for	   biomarker	   discovery	   because	   they	   are	   unbiased.	   They	   allow	   the	  simultaneous	   evaluation	   of	   hundreds	   to	   thousands	   metabolites	   in	   a	   blind	   manner	  without	  a	  priori	  increasing	  the	  potential	  number	  of	  candidate	  biomarkers.	  	  One-­‐	   or	   two	   dimensional	   liquid	   or	   gaz	   chromatography	   (LC	   or	   GC)	   and	   capillary	  electrophoresis	   (CE)	   coupled	   to	  mass	   spectrometry	   (MS),	   as	  well	   as	   nuclear	  magnetic	  resonance	  (NMR),	  are	  regarded	  as	   the	  most	  powerful	   tools	   for	  establishing	   fingerprint	  profiles.	   Many	   reports	   regarding	   the	   use	   of	   these	   technologies	   in	   the	   context	   of	  metabolomic	   studies	   have	   already	   been	   published	   [26-­‐28].	   The	   separation	   techniques	  (i.e.	   LC,	   GC	   and	   CE)	   are	   very	   versatile	   approaches	   due	   to	   the	   multiple	   choices	   of	  stationary	   and	   mobile	   phases,	   as	   well	   as	   background	   electrolytes	   that	   are	   available.	  However	  that	  makes	  them	  consequently	  rather	  complex,	   time	  consuming	  and	  requires	  experienced	  staff.	  The	   earliest	   researches	   on	   metabolite	   profiling	   where	   described	   by	   GC-­‐MS.	   GC-­‐MS	   is	  highly	   selective,	   relatively	   inexpensive	   and	   provides	   reproducible	   analysis	   with	   an	  added	   advantage	   of	   comprehensive	   structured	   databases	   for	   GC-­‐MS	   metabolite	  identification.	   However,	   it	   is	   not	   a	   universal	   approach	   since	   it	   is	   limited	   to	   volatile	  
compounds	   or	   appropriately	   derivatized	   metabolites.	   The	   use	   two-­‐dimentional	  chromatography	   further	   enhances	   metabolite	   quantification	   and	   gives	   metabolomics	  platforms	  even	  greater	  analytic	  capability	  [29].	  	  Liquid	  chromatography-­‐mass	  spectrometry	  (LC-­‐MS)	  is	  the	  most	  widely	  used	  technology	  in	   metabolomic	   studies,	   due	   to	   its	   ability	   to	   separate	   and	   detect	   a	   diverse	   range	   of	  molecules	   with	   high	   sensitivity.	   Reverse-­‐phase	   (RP)-­‐LC	   is	   generally	   used	   for	   the	  separation	   of	   metabolites	   of	   medium	   to	   low	   polarity	   (i.e.	   fatty	   acids,	   flavonoïds,	  triglycerides...);	   although	   normal-­‐phase	   (NP)-­‐LC	   and	   hydrophilic	   interaction	   liquid	  chromatographic	   (HILIC)	   modes	   are	   better	   suited	   for	   the	   analysis	   of	   highly	   polar	  metabolites	   (i.e.	   glycols,	   sugars,	   amino-­‐acids,...).	   The	   combination	   of	   HILIC	   and	   RPLC	  coupled	   with	   an	  MS	   detector	   expands	   the	   number	   of	   detected	   analytes	   and	   provides	  more	   comprehensive	   metabolite	   coverage	   than	   use	   of	   only	   RP	   chromatography.	  Multidimensional	   LC	   is	   also	   frequently	  used;	   it	   combines	   generally	   two	  orthogonal	   LC	  modes	   providing	   a	   better	   selectivity.	   More	   recently	   ultra-­‐high	   pressure	   (UHPLC)	   and	  superficially	   porous	   particles	   substantially	   increased	   the	   peak	   capacity	   of	   liquid	  chromatography,	   potentially	   reducing	   coelution	   and	   enabling	   equivalent	   separation	   in	  shorter	  analysis	  times	  [30-­‐31].	  CE	   is	   nowadays	   a	   powerful	   alternative	   to	   chromatographic	   techniques	   such	   as	   GC	   or	  HPLC	   to	   carry	   out	   metabolomic	   studies.	   Today	   CE	   is	   increasingly	   used	   for	   several	  reasons:	   its	  high	  efficacy,	   versatility	   and	   feasibility	  of	   incorporating	  a	   large	  number	  of	  selectors	   in	   the	   background	   electrolyte	   that	   greatly	   facilitates	   method	   development,	  rapidity,	   cheapness	   (a	   low	   consumption	   of	   reagents),	   and	   minimum	   environmental	  impact	   with	   respect	   to	   HPLC	   or	   GC	   techniques.	   The	   high	   peak	   efficiency	   that	   can	   be	  obtained	   in	   CE	   (between	   100,000-­‐200,000	   plates	   in	   a	   typical	   capillary)	   is	   one	   of	   the	  major	  advantages	  [32].	  When	  a	  high	  selectivity	  and	  sensitivity	  is	  required,	  ultraviolet	  detection	  (UV)	  is	  not	  the	  preferred	   detection	   system.	   Mass	   spectrometry	   (MS)	   detection	   offers	   not	   only	   an	  improvement	  in	  the	  sensitivity	  but	  also	  offers	  the	  possibility	  to	  unambiguously	  identify	  an	  analyte	  by	  its	  mass	  to	  charge	  ratio	  (m/z).	  In	  addition,	  when	  MS/MS	  experiments	  are	  performed,	   structural	   information	   can	   also	   be	   obtained	   from	   the	   fragmentation	  mass	  spectrum	  which	  offers	  an	  excellent	  selectivity.	  
Traditional	  MS/MS	  analysis	  consists	  of	  a	  first	  acquisition	  of	  a	  MS	  survey	  scan	  followed	  by	   selection	   of	   precursor	   ions	   by	   the	   first	   analyser	   for	   MS/MS	   fragmentation	   and	  analysis	  by	  the	  second.	  More	  recently,	  targeted	  quantitative	  MS	  has	  been	  considered	  for	  validation	   step	  with	   the	   emergence	  of	   single-­‐	   and	  multiple-­‐	   reaction	  monitoring	   (SRM	  and	  MRM).	  The	  analytical	  system	  most	  often	  are	  constituted	  of	  a	  liquid	  chromatography	  coupled	   to	   an	   ESI-­‐triple	   quadrupole	   mass	   spectrometer	   which	   allows	   the	   absolute	  quantification	   of	   one	   or	   several	  metabolites	   in	   hundred	   complex	   samples.	   In	   a	   single	  reaction	  monitoring	  (SRM),	  the	  first	  and	  the	  third	  analysers	  act	  as	  filters	  to	  specifically	  select	  predefined	  m/z	  values	  corresponding	  to	  the	  ion	  and	  a	  specific	  fragment	  ion	  of	  this	  molecule	   respectively,	   whereas	   the	   second	   quadrupole	   serves	   as	   a	   collision	   cell.	   This	  approach	  has	  the	  advantage	  to	  offer	  the	  possibility	  of	  multiplexing	  without	  affecting	  the	  sensitivity	   and	   selectivity.	   For	   metabolic	   profiling,	   Q-­‐TOF	   mass	   analysers	   are	   most	  commonly	   used,	   due	   to	   their	   ability	   to	   provide	   the	   accurate	   high	   mass	   resolution	   of	  MS/MS	  analysis	  [33].	  Given	   the	   abundant	   and	   ubiquitous	   presence	   of	   1H	   in	   most	   metabolites,	   1D	   1H-­‐NMR	  spectroscopy	   is	   the	   primary	   source	   of	   NMR-­‐based	   metabolomics	   data,	   used	   almost	  exclusively	  to	  generate	  metabolomics	  data	  until	   the	  recent	  years.	   In	  spite	  of	  numerous	  advantages,	  which	  are	  presented	  in	  Table	  1	  in	  comparison	  with	  MS,	  the	  main	  drawback	  of	  metabolite	  analysis	  by	  NMR	  platforms	  is	  the	  sensitivity	  that	  does	  not	  match	  the	  one	  of	  MS	  based	  platforms.	  Nevertheless,	  the	  highly	  reproducible,	  quantitative	  results	  of	  NMR,	  the	   easy	   sample	   preparation	   step	   required	   for	   the	   method,	   ensure	   it	   will	   remain	  extremely	   valuable	   in	  metabolomic	   studies,	   especially	  when	   combined	  with	  MS	   based	  techniques	  [34-­‐36].	  NMR	  is	  particularly	  valuable	  in	  the	  natural	  products	  area	  where	  the	  method	  is	  highly	  helpful	  to	  identify	  unknown	  secondary	  metabolites	  [37-­‐38].	  Vibrational	  spectroscopy	  and	  more	  particularly	  Fourier	  transform	  infrared	  spectroscopy	  (FT-­‐IR)	  were	  found	  particularly	  interesting	  for	  metabolomic	  studies	  due	  to	  their	  rapid,	  high-­‐throughput	   and	   non-­‐destructive	   analysis	   of	   a	   wide	   range	   of	   sample	   types.	   The	  resultant	  infrared	  absorbance	  spectrum	  is	  characteristic	  of	  the	  functional	  groups	  within	  the	  sample	  and	  thus	  constitutes	  an	  unique	  fingerprint	  [39].	  This	  is	  a	  promising	  analytical	  tool	  for	  metabolomic	  studies	  however,	  it	  is	  important	  to	  note	  that	  the	  presence	  of	  water	  in	   a	   sample	   may	   influence	   the	   bands	   at	   certain	   specific	   wave	   number	   and	   that	  
environmental	   conditions	   around	   the	   FT-­‐IR	   instrument	   can	   cause	   variations	   in	   the	  spectra.	  Moreover	  a	  strong	  expertise	  in	  the	  chemometric	  analysis	  of	  spectra	  is	  required.	  It	   is	   worth	   noting	   that	   an	   intrinsic	   disadvantage	   of	   in	   vitro	   and	   ex	   vivo	   metabolomic	  experiments	  is	  the	  loss	  of	  information	  regarding	  the	  subcellular	  and	  cellular	  localization	  of	  the	  metabolites.	  Recently,	  imaging	  mass	  spectrometry	  (IMS)	  and	  magnetic	  resonance	  imaging	   (MRI)	  have	  been	   introduced	  providing	   information	  about	   spatial	   distribution.	  This	   technique	   allow	   spatial	   mapping	   of	   lipids,	   peptides	   or	   drugs	   in	   fixed	   samples,	  without	   extraction	   and	   loss	   of	   cellular	   architecture.	   This	   approach	   is	   very	   promising	  improving	  our	  understanding	  of	  cellular	  physiology	  and	  enzyme	  function	  [40].	  	  	  All	   those	   analytical	   tools	   provide	   complementary	  metabolic	   information	   and	   it	   is	   thus	  recommended	  to	  use	  then	  in	  combination.	  	  
Other	  challenges	  Recent	   interest	   in	   the	   field	   has	   yielded	   a	   large	   number	   of	   candidate	   biomarkers	   in	  various	   diseases.	   However,	   the	   small	   size	   and	   poor	   design	   of	   some	   studies	   drove	  validation	   of	   these	   biomarkers	   quite	   challenging	   [41].	   Critical	   steps	   that	   should	   be	  undertaken	  to	  avoid	  any	  bias,	  to	  maximize	  reproducibility	  and	  detection	  sensitivity,	  with	  the	  final	  aim	  to	  find	  relevant,	  specific	  and	  robust	  biomarkers	  should	  be	  addressed.	  	  All	   these	   difficulties	   can	   be	   addressed	   only	   by	   substantial	   reduction	   in	   sample	  complexity	   and	   the	   application	   of	   a	   rigorous	   standardization	   program	   of	   the	   entire	  analytical	  process.	  This	   involves	  a	   fully	  operational	   and	  calibrated	   instrument	  and	   the	  use	   of	   suitable	   QC	   samples,	   similar	   in	   nature	   and	   complexity	   to	   the	   studied	   samples.	  Indeed,	   the	   use	   of	   relevant	   quality	   controls	   (QCs)	   is	   highly	   recommended	   and	   even	  mandatory	   in	   such	  applications.	  One	  of	   the	  most	   challenging	  aspects	   in	   studying	  body	  fluids	  metabolic	  profiles	  is	  the	  sample	  preparation	  which	  remains	  a	  laborious	  and	  time	  consuming	   task	   as	   it	   usually	   needs	   enrichment	   and	   purification	   before	   sequencing	   by	  MS-­‐MS.	   Ideally,	   sample	   preparation	  methods	   should	   be	   high-­‐throughput,	   reproducible	  and	  preserve	  quantitative	   information.	   In	  addition,	   they	  should	  avoid	   loss	  and	  dilution	  of	  samples	  as	  well	  as	  to	  be	  compatible	  with	  downstream	  analytic	  techniques.	  In	  order	  to	  enlarge	   dynamic	   range	   and	   thus	   metabolite	   coverage,	   several	   complementary	  
techniques	   of	   preparation	   can	   be	   combined.	   The	   use	   of	   orthogonal	   techniques	   is	   also	  mandatory	   to	   provide	   valuable	   information	   for	   the	   identification	   of	   unknown	  metabolites.	  Another	  important	  methodological	  source	  of	  artefacts	  is	  the	  data	  analysis	  of	  metabolite	  profiles.	  The	  data	  pre-­‐processing	   (calibration,	  baseline	   correction,	  normalization,	  peak	  detection	  and	  peak	  alignment)	  represents	  a	  key	  step	  for	  metabolomic	  analysis	  [41].	  	  Besides	   the	   instrumentation	   and	   the	   methodologies	   related	   to	   chromatography-­‐mass	  spectrometry	  analysis,	  the	  nature,	  quality	  and	  number	  of	  clinical	  samples	  to	  process	  and	  statistical	  data	   treatment	  are	  also	  key	  elements	   to	  be	  considered	   for	  any	  metabolomic	  approaches.	  	  	  
Conclusions	  Taking	   into	   account	   herein	   and	   previously	   described	   recommendations,	   metabolomic	  approaches	   offer	   very	   exciting	   opportunities	   to	   discover	   not	   only	   diagnostic,	   but	  prognostic	  and	  also	  mechanistic	  markers	  for	  a	  number	  of	  major	  diseases.	  This	  could	  lead	  to	  the	  identification	  of	  new	  targets	  and	  then	  new	  drugs	  with	  original	  modes	  of	  action.	  It	  is	   also	   expected	   that	   the	   ability	   to	   identify	   markers	   of	   drug	   toxicity/efficacy	   will	  significantly	  accelerate	  drug	  discovery	  and	  help	  define	  the	  appropriate	  clinical	  plan.	  However,	  some	  challenges	  still	  remain,	  as	  for	  all	  other	  “omic”	  approaches,	  due	  in	  part	  to	  the	  complexity	  and	  the	  wide	  dynamic	  range	  of	  the	  samples.	  Sample	  fractionation	  and/or	  enrichment	  procedure	  will	  certainly	  be	  the	  solution	  to	  visualise	  the	  deep	  metabolome.	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  Table	  1.	  	  Comparison	  of	  main	  advantages	  and	  disadvantages	  of	  NMR	  and	  MS	  techniques	  in	  metabolomics.	  	  
Key	  points	   NMR	  techniques	   MS	  techniques	  
Detected	  
metabolites	  
Universal	  detector	   Universal	  detector	  for	  ionisable	  molecules	  
Reproducibility	   High	  reproducibility	   Lower	  reproducibility	  than	  NMR	  (especially	  when	  combined	  with	  LC)	  
Sensitivity	   Low	  sensitivity	  (µg)	   High	  sensitivity	  (ng)	  
Resolution	   Low	  resolution	  but	  could	  be	  improved	  by	  2D-­‐methods	   High	  resolution	  
Quantitativity	   Quantitation	  possible	  (no	  standard	  required)	   Quantitation	  possible	  (standard	  required)	  
Sample	  
preparation	  
Minimal	   Sample	  preparation	  required	  
Structural	  
informations	  
Gives	  structural	  informations	  to	  identify	  metabolites	   Gives	  structural	  informations	  to	  identify	  metabolites	  
Other	   Non	  destructive	  method	   Destructive	  method	  	  
	  
	   	  
Figure	  1:	  Place	  of	  metabolomics	  amongst	  other	  “omics”	  sciences.	  	  
	  	  
	   	  
Figure	  2	  :	  Evolution	   of	   the	   number	   of	   publications	   per	   year	   using	   the	   terms	   “metabolomics”,	   or	  “metabolomics”	  and	  “metabonomics”	  or	  “metabonomic”.	  The	  data	  were	  obtained	  using	  the	  search	  engine	  Pubmed.	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